Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.43 | N/A | +35.63% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.43 | N/A | +35.63% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed optimism about ongoing projects and their potential impact. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted progress in clinical trials.
They emphasized their commitment to advancing their pipeline.
No specific guidance was provided for future quarters.
Protagonist Therapeutics reported a better-than-expected EPS, which indicates some positive momentum in their financials. However, the stock reacted slightly down by 0.1%, likely due to the lack of revenue information and no guidance for future performance. Investors may be cautious as they await more detailed updates on the company's pipeline and financial outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022